IDEAS home Printed from https://ideas.repec.org/r/wly/hlthec/v13y2004i5p405-415.html
   My bibliography  Save this item

Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questions

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
  2. Michał Jakubczyk & Bogumił Kamiński, 2017. "Fuzzy approach to decision analysis with multiple criteria and uncertainty in health technology assessment," Annals of Operations Research, Springer, vol. 251(1), pages 301-324, April.
  3. Ifigeneia Mavranezouli & Joran Lokkerbol, 2017. "A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder," PharmacoEconomics, Springer, vol. 35(3), pages 271-296, March.
  4. Hanna Waart & Johanna M. Dongen & Wim H. Harten & Martijn M. Stuiver & Rosalie Huijsmans & Jeannette A. J. H. Hellendoorn-van Vreeswijk & Gabe S. Sonke & Neil K. Aaronson, 2018. "Cost–utility and cost-effectiveness of physical exercise during adjuvant chemotherapy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 893-904, July.
  5. Ângela J. Ben & Jeruza L. Neyeloff & Camila F. Souza & Ana Paula O. Rosses & Aline L. Araujo & Adriana Szortika & Franciele Locatelli & Gabriela Carvalho & Cristina R. Neumann, 2020. "Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 57-68, February.
  6. Lakdawalla, Darius N. & Seabury, Seth A., 2012. "The welfare effects of medical malpractice liability," International Review of Law and Economics, Elsevier, vol. 32(4), pages 356-369.
  7. Mbathio Dieng & Nikita Khanna & Nadine A. Kasparian & Daniel S. J. Costa & Phyllis N. Butow & Scott W. Menzies & Graham J. Mann & Anne E Cust & Rachael L. Morton, 2019. "Cost-Effectiveness of a Psycho-Educational Intervention Targeting Fear of Cancer Recurrence in People Treated for Early-Stage Melanoma," Applied Health Economics and Health Policy, Springer, vol. 17(5), pages 669-681, October.
  8. O'Neill, Donal, 2009. "A Cost-Benefit Analysis of Early Childhood Intervention: Evidence from a Randomised Evaluation of a Parenting Programme," IZA Discussion Papers 4518, Institute of Labor Economics (IZA).
  9. Mohamed El Alili & Johanna M. Dongen & Judith A. F. Huirne & Maurits W. Tulder & Judith E. Bosmans, 2017. "Reporting and Analysis of Trial-Based Cost-Effectiveness Evaluations in Obstetrics and Gynaecology," PharmacoEconomics, Springer, vol. 35(10), pages 1007-1033, October.
  10. Martina Lundqvist & Jenny Alwin & Lars-Åke Levin, 2019. "Certified service dogs – A cost-effectiveness analysis appraisal," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-13, September.
  11. Nicholas Graves & Adrian G Barnett & Kate A Halton & Jacob L Veerman & Elisabeth Winkler & Neville Owen & Marina M Reeves & Alison Marshall & Elizabeth Eakin, 2009. "Cost-Effectiveness of a Telephone-Delivered Intervention for Physical Activity and Diet," PLOS ONE, Public Library of Science, vol. 4(9), pages 1-8, September.
  12. Nicholas Graves & Mary Courtney & Helen Edwards & Anne Chang & Anthony Parker & Kathleen Finlayson, 2009. "Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients," PLOS ONE, Public Library of Science, vol. 4(10), pages 1-9, October.
  13. John Mullahy, 2017. "Individual Results May Vary: Elementary Analytics of Inequality-Probability Bounds, with Applications to Health-Outcome Treatment Effects," NBER Working Papers 23603, National Bureau of Economic Research, Inc.
  14. Zoie Shui-Yee Wong & David Goldsman & Kwok-Leung Tsui, 2016. "Economic Evaluation of Individual School Closure Strategies: The Hong Kong 2009 H1N1 Pandemic," PLOS ONE, Public Library of Science, vol. 11(1), pages 1-18, January.
  15. Sood Neeraj & Philipson Tomas J. & Huckfeldt Peter, 2013. "Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors," Forum for Health Economics & Policy, De Gruyter, vol. 16(1), pages 1-22, April.
  16. Richard M. Nixon & David Wonderling & Richard D. Grieve, 2010. "Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared," Health Economics, John Wiley & Sons, Ltd., vol. 19(3), pages 316-333, March.
  17. Michal Jakubczyk, 2016. "Choosing from multiple alternatives in cost-effectiveness analysis with fuzzy willingness-to-pay/accept and uncertainty," KAE Working Papers 2016-006, Warsaw School of Economics, Collegium of Economic Analysis.
  18. Saskia Schawo & Annemarie Kolk & Clazien Bouwmans & Lieven Annemans & Maarten Postma & Jan Buitelaar & Michel Agthoven & Leona Hakkaart-van Roijen, 2015. "Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Neede," PharmacoEconomics, Springer, vol. 33(5), pages 489-509, May.
  19. Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012. "Decision-making with Uncertainty: The Value of Information," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 51, Edward Elgar Publishing.
  20. Nicolas A. Menzies & Djøra I. Soeteman & Ankur Pandya & Jane J. Kim, 2017. "Bayesian Methods for Calibrating Health Policy Models: A Tutorial," PharmacoEconomics, Springer, vol. 35(6), pages 613-624, June.
  21. S. Boyer & M. L. Nishimwe & L. Sagaon-Teyssier & L. March & S. Koulla-Shiro & M.-Q. Bousmah & R. Toby & M. P. Mpoudi-Etame & N. F. Ngom Gueye & A. Sawadogo & C. Kouanfack & L. Ciaffi & B. Spire & E. D, 2020. "Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa," PharmacoEconomics - Open, Springer, vol. 4(1), pages 45-60, March.
  22. Hoch, Jeffrey S. & Blume, Jeffrey D., 2008. "Measuring and illustrating statistical evidence in a cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 27(2), pages 476-495, March.
  23. Francisco Jódar-Sánchez & Amaia Malet-Larrea & José Martín & Leticia García-Mochón & M. López del Amo & Fernando Martínez-Martínez & Miguel Gastelurrutia-Garralda & Victoria García-Cárdenas & Daniel S, 2015. "Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program," PharmacoEconomics, Springer, vol. 33(6), pages 599-610, June.
  24. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Nonpharmacological Interventions for Dementia Patients and their Caregivers - A Systematic Literature Review," Working Papers 2018:10, Lund University, Department of Economics.
  25. Pedram Sendi, 2021. "Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve," PharmacoEconomics, Springer, vol. 39(2), pages 161-169, February.
  26. William Hollingworth & Christopher G. Fawsitt & Padraig Dixon & Larisa Duffy & Ricardo Araya & Tim J. Peters & Howard Thom & Nicky J. Welton & Nicola Wiles & Glyn Lewis, 2020. "Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCT," PharmacoEconomics - Open, Springer, vol. 4(3), pages 427-438, September.
  27. Baptiste Leurent & Manuel Gomes & Rita Faria & Stephen Morris & Richard Grieve & James R. Carpenter, 2018. "Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial," PharmacoEconomics, Springer, vol. 36(8), pages 889-901, August.
  28. Andrew R. Willan & Matthew E. Kowgier, 2008. "Cost‐effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate," Health Economics, John Wiley & Sons, Ltd., vol. 17(7), pages 777-791, July.
  29. Sanjib Saha & Birgitta Grahn & Ulf-G. Gerdtham & Kjerstin Stigmar & Sara Holmberg & Johan Jarl, 2019. "Structured physiotherapy including a work place intervention for patients with neck and/or back pain in primary care: an economic evaluation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 317-327, March.
  30. Rahmawati, 2018. "Deconstructed CSR and Social Audit Model: Postmodernist Paradigm Observations in Luwu Mining Areas, Indonesia," GATR Journals jfbr142, Global Academy of Training and Research (GATR) Enterprise.
  31. Mohamed El Alili & Johanna M. Dongen & Keith S. Goldfeld & Martijn W. Heymans & Maurits W. Tulder & Judith E. Bosmans, 2020. "Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering," PharmacoEconomics, Springer, vol. 38(11), pages 1247-1261, November.
  32. Salah Ghabri & Françoise F. Hamers & Jean Michel Josselin, 2016. "Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health," PharmacoEconomics, Springer, vol. 34(6), pages 617-624, June.
  33. Peter Makai & Willemijn Looman & Eddy Adang & René Melis & Elly Stolk & Isabelle Fabbricotti, 2015. "Cost-effectiveness of integrated care in frail elderly using the ICECAP-O and EQ-5D: does choice of instrument matter?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(4), pages 437-450, May.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.